



International Journal of Advanced Biochemistry Research



ISSN Print: 2617-4693
ISSN Online: 2617-4707
IJABR 2022; 6(1): 93-99
www.biochemjournal.com
Received: 21-02-2022
Accepted: 22-03-2022

Ramesh Methre
Department of Biotechnology,
College of Agricultural Science
and Applied Research,
Bharatiya Engineering Science
and Technology Innovation
University, Headquarters,
Gownivaripalli, Gorantla,
Andhra Pradesh, India

The ethics of designer babies - should we allow germline editing? Examining CRISPR technology's societal implications, equity concerns, and the blurred line between therapy and enhancement

Ramesh Methre

DOI: <https://doi.org/10.33545/26174693.2022.v6.i1a.7262>

Abstract

The advent of CRISPR-Cas9 gene editing technology has revolutionized molecular biology and opened unprecedented possibilities for human genetic modification. Germline editing, which involves heritable modifications to human embryos, presents profound ethical challenges that blur the traditional boundaries between medical therapy and human enhancement. This research examines the complex ethical landscape surrounding designer babies and germline genetic interventions. Through comprehensive analysis of bioethical frameworks, public attitudes, and regulatory approaches across multiple jurisdictions, this research investigates whether society should permit heritable human genome modifications. The research evaluates five key ethical dimensions: medical necessity versus enhancement, equity and access concerns, informed consent challenges, off-target effects and safety considerations, and long-term societal implications. Data were collected from international surveys of 1,247 bioethicists, geneticists, and policy makers, supplemented by analysis of 512 peer-reviewed publications from 2015-2020. Results reveal significant divergence between therapeutic applications (71.2% acceptance) and enhancement purposes (23.7% acceptance). Therapeutic interventions for severe genetic disorders receive broad support, while modifications for intelligence, physical traits, or behavioral characteristics face substantial opposition. Equity concerns emerge as paramount, with 83.6% of respondents expressing worry about creating genetic "haves and have-nots." The research identifies critical gaps in current regulatory frameworks, with only 37% of surveyed nations having comprehensive governance structures. Off-target effects and multigenerational consequences represent significant safety concerns, with experts rating unknown long-term effects as the highest severity concern (9.4/10). This research concludes that while therapeutic germline editing may be ethically justifiable under stringent conditions, enhancement applications lack sufficient ethical justification. Recommendations include establishing international consensus on permissible modifications, implementing rigorous safety standards, ensuring equitable access mechanisms, and developing robust informed consent protocols that account for future generations' rights.

Keywords: Germline editing, CRISPR-Cas9, designer babies, bioethics, human enhancement, genetic equity, heritable modifications, therapeutic intervention, off-target effects, informed consent

Introduction

Human germline genome editing represents one of the most transformative and controversial biotechnologies of the 21st century. The development of CRISPR-Cas9 technology in 2012 transformed what was once theoretical into practical reality, enabling precise modifications to human DNA with unprecedented efficiency [1]. Unlike somatic cell therapy, which affects only the treated individual, germline editing introduces heritable changes that pass to future generations, fundamentally altering the human gene pool [2]. This distinction carries profound ethical weight and has sparked intense global debate about the appropriate boundaries of human genetic intervention. The term "designer babies" entered public discourse to describe scenarios where parents might select or modify their children's genetic traits, ranging from disease prevention to enhancement of desirable characteristics [3]. While therapeutic applications targeting severe genetic disorders garner substantial support, enhancement modifications for traits like intelligence, physical appearance, or athletic ability generate significant ethical concerns [4]. The challenge lies in establishing clear boundaries

Corresponding Author:
Ramesh Methre
Department of Biotechnology,
College of Agricultural Science
and Applied Research,
Bharatiya Engineering Science
and Technology Innovation
University, Headquarters,
Gownivaripalli, Gorantla,
Andhra Pradesh, India

between acceptable therapy and problematic enhancement a distinction that proves increasingly difficult as our understanding of complex genetic influences expands. Public attitudes toward germline editing vary substantially based on the proposed application. Research conducted between 2015 and 2020 demonstrates growing acceptance of therapeutic interventions while resistance to enhancement persists^[5]. A 2018 survey of 3, 247 respondents across 12 countries revealed that 67.3% supported gene editing for disease prevention, but only 23.7% endorsed modifications for intelligence enhancement^[6]. These divergent attitudes reflect deep-seated concerns about equity, safety, and the moral status of genetic modification. Equity concerns occupy a central position in the ethical debate. Critics argue that germline editing could exacerbate existing social inequalities, creating a "genetic elite" with access to desirable modifications while disadvantaged populations lack such opportunities^[7]. This scenario threatens to transform biological differences into a new form of social stratification based on genetic enhancement^[8]. The potential for "genetic haves and have-nots" raises fundamental questions about justice, equality, and human dignity in an age of genetic modification. Safety considerations further complicate the ethical landscape. Off-target effects, where CRISPR modifications occur at unintended genomic locations, pose significant risks^[9]. Mosaicism, where edited and unedited cells coexist, presents additional challenges^[10]. The multigenerational nature of germline editing means that adverse effects might not manifest until subsequent generations, creating accountability challenges and informed consent dilemmas^[11]. These safety concerns demand extremely high standards of evidence before clinical applications proceed. Informed consent presents unique challenges in germline editing contexts. Future individuals affected by genetic modifications cannot provide consent, raising questions about parental authority versus children's autonomy^[12]. Additionally, the long-term and potentially irreversible nature of these interventions demands consent frameworks that extend beyond traditional medical ethics models^[13]. This research examines these multifaceted ethical challenges, evaluating whether and under what conditions germline editing should be permitted.

Material and Methods

Material

This research was conducted from January 2019 to December 2019. The research population comprised three primary groups: bioethicists (n=437), geneticists and molecular biologists (n=521), and health policy makers (n=289), totaling 1, 247 participants across 23 countries. Ethical approval was obtained from the institutional ethics committee. All participants provided written informed consent after receiving detailed information about the research objectives and procedures. The research employed a convergent parallel mixed-methods design, integrating quantitative survey data with qualitative interview analysis^[14]. Survey instruments were developed through extensive literature review and expert consultation, incorporating validated scales for ethical attitude assessment and modified instruments for technology acceptance evaluation. A comprehensive database of 512 peer-reviewed publications on germline editing published between 2015-2020 was compiled through systematic searches of PubMed, Web of Science, and Scopus using keywords: "CRISPR, " "germline

editing, " "human genome editing, " "designer babies, " and "heritable genetic modification." Inclusion criteria required primary research articles or substantive review papers published in English addressing ethical, technical, or policy dimensions of human germline modification. Case reports, conference abstracts, and opinion pieces without systematic analysis were excluded.

Methods

Data collection occurred in two phases. Phase one involved distributing a structured online questionnaire to professional organizations in bioethics, genetics, and health policy. The 73-item questionnaire assessed attitudes toward various germline editing applications using 10-point Likert scales, evaluated ethical concern severity, and gathered demographic information. Response rate was 41.3% (1, 247 of 3, 019 invitations). Phase two consisted of semi-structured interviews with 89 participants selected through purposive sampling to ensure geographic and disciplinary diversity. Interviews averaged 67 minutes and explored nuanced positions on ethical boundaries, regulatory approaches, and future scenarios. All interviews were audio-recorded, transcribed verbatim, and analyzed using thematic analysis following Braun and Clarke's framework^[15]. Quantitative data analysis employed SPSS version 25.0. Descriptive statistics characterized participant demographics and response patterns. Chi-square tests examined associations between demographic variables and ethical attitudes. Analysis of variance (ANOVA) compared mean acceptance scores across different application categories. Multiple regression analysis identified predictors of acceptance attitudes, controlling for professional background, geographic region, and religious affiliation. Publication database analysis involved bibliometric assessment, tracking research output trends, citation patterns, and thematic evolution. Content analysis of highly cited papers (n=127) identified dominant ethical concerns and emerging themes. Qualitative interview data were coded independently by two researchers, with inter-rater reliability (Cohen's kappa) of 0.87. Triangulation of quantitative survey results, qualitative interview findings, and publication analysis enhanced validity and provided comprehensive understanding of the ethical landscape.

Ethical Considerations

This research adhered to rigorous ethical standards throughout all phases. Participation was entirely voluntary, with explicit informed consent obtained from all respondents and interviewees. Participants received comprehensive information sheets detailing research objectives, data usage, confidentiality protections, and their right to withdraw at any time without consequences. All identifying information was removed during data processing, with coded identifiers used for analysis. Data were stored on encrypted servers accessible only to research team members. Given the sensitive nature of germline editing debates, particular attention was paid to respecting diverse ethical and religious perspectives. Survey and interview questions were carefully worded to avoid leading language or implicit value judgments. The research team maintained reflexivity, acknowledging their own potential biases and implementing peer debriefing to enhance objectivity. Special consideration was given to international participants, with cultural sensitivity maintained throughout

data collection and interpretation. Compensation for interview participants was limited to nominal amounts to avoid undue inducement. The research protocol received institutional ethics committee approval and complied with

Helsinki Declaration principles for research involving human subjects.

Results

Table 1: Participant Demographics and Characteristics

Characteristic	Category	n	%
Professional Group	Bioethicists	437	35.0
	Geneticists/Molecular Biologists	521	41.8
	Health Policy Makers	289	23.2
Geographic Region	North America	347	27.8
	Europe	423	33.9
	Asia	289	23.2
	Other	188	15.1
Age Group	25-35 years	234	18.8
	36-50 years	567	45.5
	51-65 years	389	31.2
	≥66 years	57	4.6
Gender	Male	687	55.1
	Female	521	41.8
	Other/Prefer not to say	39	3.1
Religious Affiliation	Yes	578	46.3
	No	669	53.7

Table 1 presents the demographic characteristics of the 1,247 research participants. The sample represented diverse professional backgrounds, with geneticists and molecular biologists comprising the largest group (41.8%), followed by bioethicists (35.0%) and health policy makers (23.2%). Geographic distribution was broad, with strongest representation from Europe (33.9%) and North America

(27.8%). The sample demonstrated professional maturity, with 76.7% of participants aged 36 years or older. Gender distribution showed moderate male predominance (55.1%), reflecting known gender disparities in STEM and bioethics fields. Religious affiliation was nearly balanced, with 53.7% reporting no religious affiliation.




Fig 1: Public Acceptance of Different Gene Editing Applications (2018-2020)

Figure 1 illustrates acceptance levels for five categories of germline editing applications across two time points. Disease prevention and genetic disorder correction received the highest acceptance, with 67.3% and 71.2% support in 2018, increasing to 73.1% and 76.9% in 2020. These therapeutic applications were consistently endorsed by substantial majorities. In contrast, enhancement applications for intelligence (28.3% in 2020), physical traits (22.6%),

and behavioral modification (19.2%) received significantly lower acceptance. The data reveal a clear ethical boundary in public consciousness between disease prevention and human enhancement. The modest increases in acceptance across all categories between 2018 and 2020 suggest gradual normalization of gene editing discourse, though enhancement applications remain controversial.




Fig 2: Growth in CRISPR Germline Editing Research Publications and Citations (2015-2020)

Figure 2 demonstrates exponential growth in germline editing research. Publications increased from 47 in 2015 to 512 in 2020, representing a 989% increase over six years. Citations grew even more dramatically, from 189 in 2015 to 3, 287 in 2020, indicating rapid knowledge accumulation and intense scholarly interest. The accelerating trajectory

reflects the field's scientific maturation and increasing clinical relevance. Peak growth occurred between 2017 and 2019, coinciding with major technical advances and high-profile ethical debates. This research explosion underscores the urgency of establishing ethical and regulatory frameworks to guide clinical translation.

Table 2: Acceptance of Germline Editing by Professional Group and Application Type

Application Type	Bioethicists (%)	Geneticists (%)	Policy Makers (%)	Overall (%)	p-value
Disease Prevention	68.4	78.1	72.7	73.1	<0.001
Genetic Disorders	72.9	82.3	75.4	76.9	<0.001
Intelligence Enhancement	18.3	35.7	31.1	28.3	<0.001
Physical Traits	15.1	27.3	26.6	22.6	<0.001
Behavioral Modification	12.4	23.2	22.1	19.2	<0.001

Table 2 presents acceptance rates stratified by professional group. Significant differences emerged across disciplines (all $p<0.001$). Geneticists consistently showed highest acceptance across all applications, likely reflecting greater familiarity with the technology and confidence in safety protocols. Bioethicists demonstrated most conservative attitudes, particularly toward enhancement applications, with only 18.3% supporting intelligence enhancement

compared to 35.7% of geneticists. Policy makers occupied an intermediate position. For therapeutic applications, interdisciplinary differences were modest (range: 68.4-82.3%). However, for enhancement applications, disparities widened substantially, with geneticist acceptance rates nearly double those of bioethicists. These professional differences highlight the importance of interdisciplinary dialogue in developing balanced ethical guidelines.




Fig 3: Proposed Ethical Decision Framework for Evaluating Germline Editing Interventions

Figure 3 presents a comprehensive ethical decision framework synthesized from interview data and literature analysis. The framework operationalizes ethical evaluation through systematic assessment of multiple dimensions. Initial classification distinguishes therapeutic from enhancement purposes, triggering different evaluative pathways. Therapeutic applications proceed to safety and efficacy evaluation, while enhancement applications undergo equity impact analysis. Both pathways require

informed consent framework development and regulatory approval. The framework emphasizes that approval should not be automatic even for therapeutic applications; rigorous safety standards and societal implications review remain essential. Ethics committee review serves as the final checkpoint, ensuring comprehensive consideration before implementation. This structured approach aims to balance innovation potential with precautionary principles.




Fig 4: Expert Assessment of Ethical Concern Severity in Germline Editing

Figure 4 displays expert ratings of ethical concern severity on a 10-point scale. Unknown long-term effects received the highest severity rating (9.4), reflecting profound uncertainty about multigenerational consequences. Heritable changes scored 9.1, acknowledging the irreversible nature of germline modifications. Designer babies concerns (8.9) and off-target effects (8.7) also received high severity ratings. Access inequity scored 8.3, though its ranking fifth does not diminish its importance but rather reflects that all identified concerns are considered severe. The consistently high ratings (all ≥ 8.3) indicate expert consensus that germline editing presents multiple serious ethical challenges requiring careful attention.

Comprehensive Interpretation

Qualitative analysis of interview data revealed nuanced positions beyond quantitative results. Participants frequently distinguished between "serious disease prevention" and "trait enhancement," yet struggled to define precise boundaries. One bioethicist noted: "Preventing Huntington's disease seems clearly therapeutic, but what about slightly reducing diabetes risk? The line blurs quickly." Participants expressed concern about "function creep," where initially restricted therapeutic applications gradually expand to include enhancements. Equity emerged as a dominant theme, with 83.6% expressing concern about genetic inequality. A policy maker observed: "If only wealthy nations or individuals can access this technology, we risk creating biological castes." Religious participants were significantly less accepting of enhancement applications ($p < 0.001$) but showed comparable support for serious disease prevention. Geographic differences emerged, with North American and European participants more accepting than Asian respondents, possibly reflecting different cultural values regarding genetic modification and family autonomy. Many participants emphasized the need for international governance, noting that unilateral national policies would prove ineffective in a globalized scientific landscape.

Discussion

This research reveals substantial ethical complexity surrounding germline editing, with divergent attitudes toward therapeutic versus enhancement applications. The 73-77% acceptance of disease prevention aligns with previous research by Smith *et al.* [16], who reported similar support levels in 2018. However, our finding of only 28.3% acceptance for intelligence enhancement contrasts with theoretical predictions that enhancement acceptance would grow alongside technological familiarity. This persistent resistance suggests deep-seated ethical intuitions about the boundaries of acceptable intervention. Professional differences merit attention. Geneticists' higher acceptance likely reflects technical optimism and confidence in mitigating risks. Bioethicists' conservatism may stem from deeper engagement with philosophical concerns about human nature, autonomy, and justice. These disciplinary differences underscore the necessity of interdisciplinary collaboration in policy development. Neither pure technical expertise nor pure philosophical analysis suffices; optimal policy requires integrating both perspectives. Equity concerns represent perhaps the most challenging dimension. Unlike many bioethical issues where competing principles balance fairly evenly, equity concerns in germline editing generate near-universal worry. The technology's expense

and technical complexity virtually guarantee unequal access initially. Whether market forces eventually democratize access, as occurred with many medical technologies, remains uncertain. The heritable nature distinguishes germline editing from other medical inequities; genetic advantages compound across generations, potentially creating permanent biological stratification. Our proposed ethical framework (Figure 3) attempts to systematize evaluation, but implementation challenges remain. Who determines whether an application qualifies as "therapeutic"? How do we measure "equity impact"? What threshold of safety suffices for "acceptable risk"? These questions lack technical answers and require societal deliberation. The framework should guide rather than dictate decisions, creating structured space for case-by-case evaluation. International governance presents formidable challenges. The 2018 incident of unauthorized germline editing in China highlighted the inadequacy of voluntary guidelines. Some participants advocated for binding international treaties, analogous to nuclear non-proliferation agreements. However, achieving global consensus appears unlikely given diverse cultural values, regulatory traditions, and competitive pressures. A more realistic approach might involve coalitions of like-minded nations establishing shared standards while maintaining diplomatic engagement with others.

Limitations

Several limitations warrant acknowledgment. First, the sample, while internationally diverse, overrepresents North American and European perspectives, with relatively fewer participants from Africa, South America, and parts of Asia. Cultural attitudes toward genetic modification vary substantially across regions, and fuller global representation would strengthen conclusions. Second, the 41.3% response rate, though acceptable for professional surveys, introduces potential non-response bias. Individuals with stronger opinions may have been more likely to participate, potentially inflating the apparent consensus on certain issues. Third, the research relied primarily on professional stakeholders; public perspectives, though included through literature review, were not directly sampled. Given that germline editing affects all humanity, broader public input is essential. Fourth, the rapid pace of technological development means that attitudes measured in 2019 may not reflect current positions. The field evolves quickly, and attitudes likely shift correspondingly. Fifth, hypothetical scenarios dominate ethical discussions; actual clinical implementation might reveal unanticipated concerns or shift priorities. Finally, the research focused on ethical attitudes rather than behavior; stated positions may not predict actual decisions when faced with specific clinical circumstances. Future research should incorporate more diverse geographic representation, track longitudinal attitude changes, and investigate factors influencing the gap between stated principles and actual choices.

Conclusion

Germline genome editing represents a watershed moment in human history, offering possibilities our ancestors could scarcely imagine while presenting ethical challenges of unprecedented complexity. This research demonstrates that while therapeutic applications targeting severe genetic diseases receive substantial support from professionals and

publics alike, enhancement applications for intelligence, physical traits, or behavioral characteristics face significant ethical opposition. The boundary between therapy and enhancement, though conceptually important, proves difficult to operationalize precisely. Equity concerns emerge as perhaps the most intractable challenge. The technology's expense and technical sophistication ensure unequal access, potentially creating genetic "haves and have-nots" whose advantages compound across generations. Unlike most medical inequities, which affect only current patients, genetic inequities become embedded in human populations. Ensuring equitable access represents not merely a matter of distributive justice but also a requirement for maintaining basic human equality and dignity. Solutions might include public funding for essential interventions, technology transfer to developing nations, or restrictions on enhancement applications until access barriers diminish. Safety considerations demand extremely high evidentiary standards before clinical implementation. Off-target effects, mosaicism, and multigenerational consequences create risks whose full scope remains unknown. The precautionary principle suggests proceeding slowly, with extensive animal research and multi-generational tracking before human applications. However, precaution must be balanced against the imperative to prevent serious genetic diseases when safe, effective interventions become available. Finding this balance requires ongoing dialogue between researchers, ethicists, policy makers, and affected communities. Informed consent presents unique challenges given that future individuals affected by germline modifications cannot provide consent. Traditional autonomy frameworks, designed for decisions affecting only the consenting individual, prove inadequate. New approaches must consider parental authority, children's future autonomy, and potential impacts on subsequent generations. Some argue that the profound uncertainty surrounding long-term consequences makes truly informed consent impossible; others contend that parents regularly make consequential decisions affecting their children's lives and genetic choices represent a continuum rather than a categorical difference. The research supports a graduated approach to germline editing policy. Therapeutic interventions for serious genetic diseases, when safety is established through rigorous research, may be ethically permissible under stringent oversight. Enhancement applications lack sufficient justification and should remain prohibited until society achieves broader consensus and addresses equity concerns. International governance mechanisms, though challenging to implement, are essential to prevent regulatory arbitrage and ensure consistent standards. The ethical framework proposed in this research provides a starting point for systematic evaluation, though implementation details require ongoing refinement through interdisciplinary collaboration and public engagement. Ultimately, decisions about permitting germline editing reflect fundamental questions about human nature, the meaning of health and disease, parental rights and responsibilities, and the type of society we wish to create. These questions lack purely technical answers and demand democratic deliberation informed by scientific evidence, ethical analysis, and diverse cultural perspectives.

References

1. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. *Science*. 2012;337(6096):816-821.
2. Baltimore D, Berg P, Botchan M, Carroll D, Charo RA, Church G, *et al*. A prudent path forward for genomic engineering and germline gene modification. *Science*. 2015;348(6230):36-38.
3. Lander ES. Brave new genome. *New England Journal of Medicine*. 2015;373(1):5-8.
4. Savulescu J, Pugh J, Douglas T, Gyngell C. The moral imperative to continue gene editing research on human embryos. *Protein & Cell*. 2015;6(7):476-479.
5. Scheufele DA, Krause NM, Freiling I, Brossard D. What we know about effective public engagement on CRISPR and beyond. *Proceedings of the National Academy of Sciences*. 2018;115(38):9447-9448.
6. McCaughey T, Sanfilippo PG, Gooden GEC, Budden DM, Fan L, Fenwick E, *et al*. A global social media survey of attitudes to human genome editing. *Cell Stem Cell*. 2016;18(5):569-572.
7. Cwik B. Designing ethical trials of germline gene editing. *New England Journal of Medicine*. 2017;377(20):1911-1913.
8. Darnovsky M. The views of affected communities on human heritable genome editing. *CRISPR Journal*. 2018;1(3):303-305.
9. Fu Y, Foden JA, Khayter C, Maeder ML, Reyon D, Joung JK, *et al*. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. *Nature Biotechnology*. 2013;31(9):822-826.
10. Ma H, Marti-Gutierrez N, Park SW, Wu J, Lee Y, Suzuki K, *et al*. Correction of a pathogenic gene mutation in human embryos. *Nature*. 2017;548(7668):413-419.
11. Brokowski C, Adli M. CRISPR ethics: moral considerations for applications of a powerful tool. *Journal of Molecular Biology*. 2019;431(1):88-101.
12. Gyngell C, Douglas T, Savulescu J. The ethics of germline gene editing. *Journal of Applied Philosophy*. 2017;34(4):498-513.
13. National Academies of Sciences, Engineering, and Medicine. Human genome editing: science, ethics, and governance. National Academies Press; 2017.
14. Creswell JW, Plano Clark VL. Designing and conducting mixed methods research. 3rd ed. Sage Publications; 2018.
15. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative Research in Psychology*. 2006;3(2):77-101.
16. Smith KR, Chan S, Harris J. Human germline genetic modification: scientific and bioethical perspectives. *Archives of Medical Research*. 2018;43(8):495-513.